Role of the NO-GC/cGMP signaling pathway in platelet biomechanics
Platelets. 2024 Dec;35(1):2313359. doi: 10.1080/09537104.2024.2313359. Epub 2024 Feb 14.ABSTRACTCyclic guanosine monophosphate (cGMP) is a second messenger produced by the NO-sensitive guanylyl cyclase (NO-GC). The NO-GC/cGMP pathway in platelets has been extensively studied. However, its role in regulating the biomechanical properties of platelets has not yet been addressed and remains unknown. We therefore investigated the stiffness of living platelets after treatment with the NO-GC stimulator riociguat or the NO-GC activator cinaciguat using scanning ion conductance microscopy (SICM). Stimulation of human and murine pla...
Source: Platelets - February 14, 2024 Category: Hematology Authors: Aylin Balmes Johanna G Rodr íguez Jan Seifert Daniel Pinto-Quintero Akif A Khawaja Marta Boffito Maike Frye Andreas Friebe Michael Emerson Francesca Seta Robert Feil Susanne Feil Tilman E Sch äffer Source Type: research
Abacavir induces the transcriptional activity of YY1 and other oncogenic transcription factors in gastric cancer cells
Publication date: Available online 14 December 2019Source: Antiviral ResearchAuthor(s): Ponmathi Panneerpandian, Helen Jemimah Devanandan, Anantharaj Marimuthu, Chandrabose Karthikeyan, Kumaresan GanesanAbstractYin Yang 1 (YY1) is a ubiquitous transcription factor with both transcriptional activating and repressing functions. Targeting YY1 is considered as a potential therapeutic strategy for several malignancies. Telomerase Reverse Transcriptase (TERT) is also considered as a potential target for cancer therapeutics. To enable the large-scale screening and identification of potential YY1 targeting drugs, a gastric cancer ...
Source: Antiviral Therapy - December 16, 2019 Category: Virology Source Type: research
Abacavir induces the transcriptional activity of YY1 and other oncogenic transcription factors in gastric cancer cells.
Abstract
Yin Yang 1 (YY1) is a ubiquitous transcription factor with both transcriptional activating and repressing functions. Targeting YY1 is considered as a potential therapeutic strategy for several malignancies. Telomerase Reverse Transcriptase (TERT) is also considered as a potential target for cancer therapeutics. To enable the large-scale screening and identification of potential YY1 targeting drugs, a gastric cancer cell line-based drug screening assay was developed. In a YY1 targeted drug repurpose screen, abacavir sulfate, a nucleoside analog reverse transcriptase inhibitor and known to target TE...
Source: Antiviral Research - December 13, 2019 Category: Virology Authors: Panneerpandian P, Devanandan HJ, Marimuthu A, Karthikeyan C, Ganesan K Tags: Antiviral Res Source Type: research
Stability behaviour of antiretroviral drugs and their combinations. 9: Identification of incompatible excipients
Publication date: Available online 8 January 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Moolchand Kurmi, Archana Sahu, Mayurbhai Kathadbhai Ladumor, Arvind Kumar Bansal, Saranjit SinghAbstractIncompatibility studies of antiretroviral drugs, viz., lamivudine (3TC), emtricitabine (FTC), abacavir sulfate (ABC), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV), efavirenz (EFV) and nevirapine (NVP) were carried out in the presence of ten selected excipients, i.e., microcrystalline cellulose, lactose monohydrate, starch, magnesium stearate, sodium lauryl sulfate, sodium starch glycolate, croscar...
Source: Journal of Pharmaceutical and Biomedical Analysis - January 9, 2019 Category: Drugs & Pharmacology Source Type: research
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro
Publication date: Available online 11 December 2018Source: Molecular and Cellular EndocrinologyAuthor(s): Giulia Brigante, Laura Riccetti, Clara Lazzaretti, Laura Rofrano, Samantha Sperduti, Francesco Potì, Chiara Diazzi, Flavia Prodam, Giovanni Guaraldi, Andrea G. Lania, Vincenzo Rochira, Livio CasariniAbstractGrowth Hormone (GH) deficiency is frequent in HIV-infected patients treated with antiretroviral therapy. We treated GH3 cells with antiretrovirals (nevirapine, ritonavir or abacavir sulfate; 100 pM-1 mM range), after transfection with human growth hormone releasing hormone (GHRH) receptor cDNA. Cells viability, i...
Source: Molecular and Cellular Endocrinology - December 11, 2018 Category: Endocrinology Source Type: research
Stability behaviour of antiretroviral drugs and their combinations. 5: Characterization of novel degradation products of abacavir sulfate by mass and nuclear magnetic resonance spectrometry
Publication date: 5 February 2017 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 134 Author(s): Moolchand Kurmi, Archana Sahu, Saranjit Singh In the present study, degradation behaviour of abacavir sulfate was evaluated in solution and solid stress conditions. Solution state studies resulted in formation of eleven degradation products; of which two were also formed on solid stress. The same were separated by high performance liquid chromatography. They were characterized using liquid chromatography-high resolution mass spectrometry, liquid chromatography-multistage mass spectrometry and hydrogen/deut...
Source: Journal of Pharmaceutical and Biomedical Analysis - December 19, 2016 Category: Drugs & Pharmacology Source Type: research
Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
Conclusion Switching from TDF/FTC to ABC/3TC resulted in significantly increased LDL, HDL, and TC levels.
PMID: 27904105 [PubMed - in process] (Source: Internal Medicine)
Source: Internal Medicine - December 3, 2016 Category: Internal Medicine Tags: Intern Med Source Type: research
Abacavir/Lamivudine/ Zidovudine
Abacavir/lamivudine/zidovudine (Trizivir) is a fixed-dose tablet that contains three synthetic nucleoside analogues: abacavir sulfate, lamivudine, and zidovudine. Each tablet contains abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg, each of which inhibits HIV-1 viral reverse transcriptase. [#] (Source: Aids Info Drugs)
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research
Abacavir/Lamivudine
EPZICOM Tablets contain the following 2 synthetic nucleoside analogues: abacavir sulfate (ZIAGEN, also a component of TRIZIVIR) and lamivudine (also known as EPIVIR or 3TC) with inhibitory activity against HIV-1.
EPZICOM Tablets are for oral administration. Each orange, film-coated tablet contains the active ingredients 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine, and the inactive ingredients magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablets are coated with a film (OPADRY® orange YS-1-13065-A) that is made of FD&C Yellow No. 6, hypromellose, polyethylene gl...
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research
Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post‐marketing surveillance in Japan
ConclusionsThe post‐marketing surveillance indicated that the incidence of both ischaemic heart disease and hypersensitivity associated with Epzicom was considerably low, suggesting that this drug can be safely used in the Japanese population. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - March 3, 2014 Category: Drugs & Pharmacology Authors: Tomoko Kurita, Tomomi Kitaichi, Takako Nagao, Toshiyuki Miura, Yoshifumi Kitazono Tags: Original Report Source Type: research
Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan
ConclusionsDuring the mandatory postmarketing survey of Ziagen, there were no cases of ischemic heart diseases, and the incidence of hypersensitivity was considerably low. These indicated that abacavir can be safely used in Japanese HIV+ population. However, the safety profile of Ziagen should be continued to be monitored through pharmacovigilance. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - February 1, 2014 Category: Drugs & Pharmacology Authors: Tomoko Kurita, Tomomi Kitaichi, Takako Nagao, Toshiyuki Miura, Yoshifumi Kitazono Tags: Original Report Source Type: research
